Desmopressin can be discontinued in chronic post-traumatic AVP-D despite absent pituitary bright spot on MRI
Background
Patients with post-traumatic arginine vasopressin deficiency (AVP-D) often require lifelong desmopressin therapy. A common diagnostic indicator is the absence of the posterior pituitary bright spot (PPBS) on T1-weighted MRI, which is frequently associated with chronic AVP-D. However, the definitive link between a missing PPBS and irreversible AVP-D, necessitating permanent desmopressin, remains unclear. This uncertainty can lead to unnecessary long-term medication use, highlighting a critical gap in understanding the potential for endogenous vasopressin recovery years after a traumatic brain injury.
Study Design
This case series followed five patients with chronic-phase post-traumatic AVP-D, ranging from 156 to 965 days post-injury, who were transferred to a rehabilitation center. All patients had been on long-term desmopressin therapy and presented with a persistent absence of the PPBS on T1-weighted MRI at admission. The primary intervention involved a supervised, gradual tapering and eventual discontinuation of desmopressin therapy. Water balance, polyuria, and hypernatremia were monitored as key clinical endpoints. Plasma arginine vasopressin levels were measured following desmopressin withdrawal in some cases.
Results
Despite the persistent absence of the posterior pituitary bright spot (PPBS) on T1-weighted MRI, desmopressin therapy was successfully tapered and discontinued in all five cases. Patients maintained stable water balance without medication, showing no recurrence of polyuria or clinically significant hypernatremia during follow-up. In three of the five cases (Cases 3, 4, and 5), detectable plasma arginine vasopressin levels were observed, ranging from 1.0-1.9 pg/mL, even after desmopressin withdrawal and despite the persistent radiologic absence of the PPBS. One case (Case 3) initially presented a diagnostic challenge due to concomitant adrenal insufficiency, with resolution of AVP-D only confirmed after glucocorticoid stabilization. This suggests that endogenous vasopressin secretion can recover or be retained years after injury.
Endogenous vasopressin secretion was retained in selected patients with chronic TBI, even when MRI suggested persistent neurohypophyseal abnormalities, challenging the notion that absent PPBS signifies lifelong AVP-D.
Key Findings
- Desmopressin was successfully discontinued in all five patients with chronic post-traumatic AVP-D.
- Patients maintained stable water balance without desmopressin, showing no recurrence of polyuria or hypernatremia.
- Absent posterior pituitary bright spot on MRI was not a definitive marker of lifelong AVP-D.
- Detectable plasma AVP levels (1.0-1.9 pg/mL) were observed in three cases post-desmopressin withdrawal.
- Endogenous vasopressin secretion can be retained years after traumatic brain injury.
Why It Matters
This case series fundamentally challenges the long-held assumption that an absent posterior pituitary bright spot on MRI definitively indicates lifelong arginine vasopressin deficiency (AVP-D). For clinicians and patients, this means that periodic reassessment and supervised trial discontinuation of desmopressin therapy should be considered in chronic post-traumatic AVP-D, even years after the initial injury. It suggests that endogenous vasopressin function may recover or persist unrecognized, potentially allowing patients to avoid unnecessary long-term medication and its associated risks. This finding could lead to revised clinical protocols, emphasizing dynamic evaluation over static imaging markers, and offers hope for improved quality of life for individuals managing chronic AVP-D.
desmopressin
arginine-vasopressin-deficiency
tbi
neuroendocrinology
case-series
pituitary